Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 10/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1003862 | 0.78 | ALDH1A1 (0.46) | ARCYP2A6ALDH1A1TSHRPKM | |
| SCHEMBL306406 | 0.77 | AR (0.42) | ARCYP2A6ALDH1A1TSHRPKM | |
| SCHEMBL30361887 | 0.76 | TSHR (0.52) | ARCYP2A6ALDH1A1TSHRPKM | |
| SCHEMBL277588 | 0.76 | TSHR (0.52) | ARCYP2A6ALDH1A1TSHRPKM | |
| SCHEMBL8237072 | 0.74 | AR (0.42) | ARCYP2A6ALDH1A1TSHRPKM | |
| SCHEMBL23192730 | 0.73 | AR (0.42) | ARCYP2A6ALDH1A1TSHRPKM | |
| SCHEMBL2614496 | 0.73 | TRPA1 (0.52) | ARCYP2A6ALDH1A1TSHRCYP11B1 | |
| SCHEMBL21872468 | 0.73 | AR (0.42) | ARCYP2A6ALDH1A1TSHRPKM | |
| SCHEMBL2434593 | 0.73 | AR (0.46) | ARCYP2A6ALDH1A1TSHRPKM | |
| SCHEMBL410587 | 0.73 | TRPV4 (0.57) | ARCYP2A6ALDH1A1CYP11B2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547713-B2 | O-pyridinequinone derivatives, the composition containing the derivatives, the process for preparation of the derivatives and the use of the derivatives | GU LIANQUAN | 2009-06-16 | — | — | US | claimed |
| US-20060111405-A1 | O-pyridinequinone derivatives, the composition containing the derivatives, the process for preparation of the derivatives and the use of the derivatives | GU LIANQUAN | 2006-05-25 | — | — | US | claimed |
| US-7547713-B2 | O-pyridinequinone derivatives, the composition containing the derivatives, the process for preparation of the derivatives and the use of the derivatives | GU LIANQUAN | 2009-06-16 | — | — | US | disclosed |
| US-20060111405-A1 | O-pyridinequinone derivatives, the composition containing the derivatives, the process for preparation of the derivatives and the use of the derivatives | GU LIANQUAN | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111405-A1 | O-pyridinequinone derivatives, the composition containing the derivatives, the process for preparation of the derivatives and the use of the derivatives | PTGS2, PTGES2, PTGES | AR 2202/4885CYP2A6 50/4885ALDH1A1 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.